Abstract: |
This review explores the latest clinical advances in the evaluation and management of hypersensitivity reactions (HSRs) to chemotherapeutic agents. There is a critical need for standardized terminology and classification systems, and we discuss improved diagnostic tools and risk-management strategies that enhance the choice of using drug challenge or drug desensitization protocols. In addition, we examine established organizational models that promote patient safety and ensure continuity of care in oncology settings. By synthesizing current knowledge and practices, this review aims to provide a comprehensive overview of the state-of-the-art clinical approaches to managing HSRs to chemotherapeutic agents, ultimately contributing to better patient outcomes and quality of care. The insights presented here underscore the importance of ongoing research and collaboration among health care professionals to refine classification systems for drug HSRs and enhance the overall management of HSRs in oncology patients. © 2025 American Academy of Allergy, Asthma & Immunology |